Collaborations and Partnerships

CBNS researchers have a long history of collaboration with other universities, research centres, industry and medical organisations. These collaborations take a wide variety of forms – from formal relationships such as Linkage Projects or contract research, to informal and ad hoc collaborations.

Intellectual Property and Commercialisation Policy

The CBNS IP and Commercialisation Committee (IPCC) provides advice for Intellectual Property (IP) management to CBNS CIs. The IPCC comprises the Centre Executive (Director, Deputy Director and Manager), plus the Business Development Manager from the Administering Organisation (Monash). In discussing IP from collaborating organisations, the IPCC co-opts the Business Development Manager (or equivalent) from that organisation.

Intellectual Property

CBNS does not own project intellectual property (IP) resulting from CBNS activities. Project IP is owned by the (administering, collaborating or partner) organisation making the major inventive contribution to the IP. Whilst a single organisation assumes control of project IP, in the cases of cross institutional participation in project IP generation, beneficial interest in project IP, is determined by relative contributions to IP generation based on cash and in-kind contributions to that project (cash is weighted by a factor of 2). CBNS maintains an Intellectual Property Register, which includes up to date details of CBNS IP and each organisation’s background IP. It consists of: • the owners of each item of background and IP and the proportion of ownership • any and all third party interests in background and IP • any patents or patent applications relating to

Commercialisation

The organisation owning the project IP supports protection and commercialisation through its IP commercialisation group and meets the cost of protection. CBNS commercial partners provide real world advice to CIs but also provide a potential path-to-market and a defined route to impact. As such, industry partners have the right of first refusal to a license to exploit project IP on terms to be agreed. In relation to the commercialisation of project IP, all parties negotiate in good faith to agree on a Commercialisation Lead and the terms of any Commercialisation.

The Commercialisation Lead has the right to sublicense project IP in the interests of all parties and CBNS, without restricting the use of the project IP for research, teaching and scholastic endeavours.

Patent applications, invention disclosures and selected commercial activities

Node Type Date Inventors/Researchers involved

Monash Provisional 7 Jan 2019 Chris Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu & others

PCT 7 Jan 2019 Chris Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu

Provisional 28 Feb 2019 Chris Porter, Natalie Trevaskis, Dan Zheng, Nathania Leong, Garima Sharma, Mitchell McInerney, Tim Quach, Sifei Han & others

Provisional 28 Feb 2019 Chris Porter, Natalie Trevaskis, Dan Zheng, Nathania Leong, Garima Sharma, Mitchell McInerney, Tim Quach, Sifei Han & others

Provisional 28 Feb 2019 Chris Porter, Natalie Trevaskis, Dan Zheng, Nathania Leong, Garima Sharma, Mitchell McInerney, Tim Quach, Sifei Han & others

Provisional 17 May 2019 Thomas Davis, Jonathan Baell, Jeroen Goos, Jason Lewis

Provisional 27 Jun 2019 Chris Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Dan Zheng, Nathania Leong, Garima Sharma, Mitchell McInerney

Provisional 19 Sep 2019 Chris Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu, Enyuan Cao, Matthew Watt

Provisional 21 Oct 2019 Simon Corrie, Julia Walker, Kristian Kempe

European patent 29 Sep 2019 Vincent Jannin, Ben Boyd, Vithani Kapilkumar

UniSA Provisional 4 Nov 2019 Azadeh Nilghaz, Ludivine Delon, Edward Cheah, Benjamin Thierry, Craig Priest

UQ Provisional 8 Nov 2019 Kris Thurecht, Vanessa Soh, Idriss Blakey, Muneer Ahamad, Ellen van Dam, Matt Harris

Provisional 8 Nov 2019 Kris Thurecht, Vanessa Soh, Idriss Blakey, Muneer Ahamad, Ellen van Dam, Matt Harris

Provisional 8 Nov 2019 Kris Thurecht, Vanessa Soh, Idriss Blakey, Muneer Ahamad, Ellen van Dam, Matt Harris

Industry and commercial engagement

CBNS researchers have a range of collaborations with commercial organisations. These relationships are typically led by one of our CIs and link with Australian and international biotech experts. The collaborations provide an opportunity for bio-nano research to be translated into product development and, ultimately, application and use. Examples include:

Further details on the range of industry and commercial engagements of CBNS can be found on our website: https://www.cbns.org.au/engagement/industrial-and-commercial-engagement/

Main Contact Company Content

Professor Kris Thurecht Aegros International Smart affinity membranes for advanced manufacturing of high value therapeutic proteins

Professor Chris Porter Capsugel Ionic liquid technology for drug delivery

Professor Benjamin Thierry Ceramisphere Ltd. – funded Development of an in vitro model of the intestinal epithelium Professor Clive Prestidge by an ARC Linkage grant to optimize oral nano-vaccine

Professor Ben Boyd Cerecin Understanding dissolution, digestion and absorption of lipids from Cerecin proprietary formulations

Professor Andrew Whittaker Dupont

Professor Benjamin Thierry Ferronova Ltd.

Professor Ben Boyd Galera Therapeutics Photo-responsive surfaces

Improving Head and Neck Cancer staging with nanoparticles

Understanding lipid and colloidal interactions with GC4419 and analogs

Professor Ben Boyd Gattefosse 3D Printing of Self-nanoemulsifying formulations

Professor Chris Porter Halozyme Therapeutics Perturbation of the extracellular architecture to promote the absorption and lymphatic transport of biological macromolecules

Professor Pall Thordarson Lleaf Pty Ltd Precision Luminescent Solar Concentrators from Robust (ARC Linkage 2017-2020) Quantum Dot Arrays

Professor Benjamin Thierry Murdoch University, WaterNSW, Development and validation of rapid detection and viability Seqwater and SA Water assays for Cryptosporidium, Norovirus, and Adenovirus and using a novel gut-on-chip

Professor Justin Gooding Nutromics Personalised Health A wearable sensor for nutrition and wellness monitoring

Professor Clive Prestidge Pharmako Biotechnology Pty Ltd Novel formulations for nutraceuticals

Professor Chris Porter PureTech Health

Professor Ben Boyd Sigrid Therapeutics

Professor Chris Porter StarPharma Dr Angus Johnston

Professor Kris Thurecht StarPharma Targeting the lymphatic system using glyceride-mimetic prodrugs

Understanding the effect of SiPore on lipid digestion and absorption

Novel targeted delivery systems

Imaging the distribution of dendritic nanomedicines

Professor Kris Thurecht Telex Pharmaceuticals Biodistribution, pharmacokinetics and efficacy of therapeutic antibodies

Professor Pall Thordarson Zhizhen Medical Co Scaling manufacture of 3-D microstructures for the medical (ARC Linkage 2018-2020) devices industry

Health and medical sector engagement

CBNS researchers have a range of links with organisations in the health and medical sector. These relationships are typically led by one of our Chief Investigators and link with hospitals and medical research institutes. The collaborations provide an opportunity for bio-nano research to be undertaken in collaboration with medical researchers and practitioners, informed by end user needs.

Further details on the range of industry and commercial engagements of CBNS can be found on our website: https://www.cbns.org.au/engagement/health-and-medical-sector-engagement/

Main Contact Company Content

Professor Stephen Kent Aarhus University Denmark Clinical trials of approaches to cure HIV

Professor Clive Prestidge Boulos & Cooper Pharma Preclinical development of the novel antibiotic Ramizol

Professor Stephen Kent Burnet Institute Melbourne Novel molecules to measure immune responses

Associate Professor John McGhee Garvan Institute

Professor Clive Prestidge Holman Pharma Pty Ltd Virtual reality cell explorer

Improving oral delivery of poorly permeable drugs

Professor Stephen Kent Imperial College London UK Clinical trials of new HIV vaccines

Professor Andrew Whittaker Institute of Nano Science and Technology, Mohali Theranostic particles

Professor Andrew Whittaker Jilin University Nanoparticles for imaging; fundamentals of polymer-Au NPs

Professor Benjamin Thierry Massachusetts General Hospital Development of bioengineered in vitro tumour & Harvard Medical School models for radiobiological studies

Professor Kris Thurecht PA Hospital, Metro South, Brisbane Brain Cancer

Professor Clive Prestidge Reform Pharm Pty Ltd

Professor Benjamin Thierry Royal Adelaide Hospital Lipoceramic reformulation of cardiovascular drugs

Smart “Nano Tracer” for improved preoperative staging with MRI and PET

Professor Benjamin Thierry Royal Adelaide Hospital Clinical trialling of Ferronva’s staging technology

Professor Andrew Whittaker Shanghai Jiao Tong University Iron Oxide NPs – responsive materials

Professor Andrew Whittaker Singapore Bioimaging Consortium (A*STAR) Cell uptake and imaging

Professor Benjamin Thierry Stanford Cancer Institute Development of nanomedicine molecular PEG tracer

Associate Professor John McGhee St Vincent’s Hospital Sydney Pain management using virtual reality

Professor Stephen Kent The University of California, Irvine Novel influenza vaccine

Professor Kris Thurecht University of Birmingham Polymeric imaging agents

Professor Andrew Whittaker University of California Santa Barbara Block copolymer self asembly

Professor Stephen Kent Vanderbilt University, USA New antibodies to treat Influenza infection

Dr Adam Wheatley Professor Stephen Kent Vaxxas Novel analyses on immune responses induced by nano patch